Asahi Glass Company Bioscience, part of Asahi Glass Company, a Tokyo-headquartered glass and chemical producer, Biomeva GmbH, a Heidelberg, Germany-based contract manufacturing organization, and CMC Biologics, a Bothell, Washington-based contract biologics manufacturer, will be integrated and newly branded as AGC Biologics, effective January 8, 2018.

CMC Biologics was acquired by AGC in February 2017, and AGC acquired Biomeva GmbH in September 2016. Subsequently, in January 2017, AGC Bioscience completed its acquisition of CMC Biologics.

AGC Biologics will offer contract development and manufacturing organization services from its facilities in the following sites: Seattle, Washington and Berkeley, California; Copenhagen, Denmark; Heidelberg, Germany; Chiba, Japan; and Yokohama, Japan. The company plans to continue its global presence with microbial and mammalian capabilities by fulfilling early-phase through late-phase projects, both at small and large-scale. The combined company currently employs more than 850 employees worldwide.

This announcement accompanies the appointment of Dr. Gustavo Mahler as president and chief executive officer (CEO) of AGC Biologics. Mahler will be responsible for the strategic development and support of the company’s future growth.

Mahler has more than 20 years of scientific and executive management experience. Mahler became president and CEO of CMC Biologics in 2015.

Source: AGC Biologics